04:39 PM EDT, 03/17/2025 (MT Newswires) -- Andrew Callos, Executive Vice President, Chief Commercial Officer, on March 17, 2025, sold 20,900 shares in Cytokinetics ( CYTK ) for $943,426. Following the Form 4 filing with the SEC, Callos has control over a total of 37,663 common shares of the company, with 37,663 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1061983/000112760225009691/xslF345X05/form4.xml